文献速递造血干细胞移植与细胞治疗

单倍体造血干细胞移植后早期停用钙调神经磷酸酶抑制剂可行:ANZHIT 1研究

Early cessation of calcineurin inhibitors is feasible post-haploidentical blood stem cell transplant: the ANZHIT 1 study.
PubMed 文献 · Blood Adv · 2023-01-01

ANZHIT-1是在6个澳大利亚异基因造血干细胞移植中心开展的单倍体移植2期研究,纳入78例血液系统恶性肿瘤患者,采用移植后环磷酰胺联合吗替麦考酚酯和钙调神经磷酸酶抑制剂预防移植物抗宿主病,并在符合条件患者中于第60天开始逐渐减量并于第120天前停用钙调神经磷酸酶抑制剂。2年无病生存率在清髓性预处理组为67.5%(95%CI 53.2-85.6),在减低强度预处理组为68.3%(95%CI 56.3-83.01),移植相关死亡率第100天和1年分别为清髓性预处理组4.9%(95%CI 1.6-15.3)和17.9%(95%CI 8.8-36.5)、减低强度预处理组3.1%(95%CI 0.8-12)和11.6%(95%CI 6-22.4),未观察到慢性移植物抗宿主病或死亡率增加。

要点

  • 2年无病生存率清髓性预处理组67.5%(95%CI 53.2-85.6),减低强度预处理组68.3%(95%CI 56.3-83.01)。
  • 计划停用钙调神经磷酸酶抑制剂的中位时间为第142.5天,未增加慢性移植物抗宿主病或死亡率。
  • 可评估患者中71.6%在移植后12个月停用免疫抑制。

核心结论

  • 这项使用移植后环磷酰胺的前瞻性单倍体造血干细胞移植试验显示出令人鼓舞的生存率,表明早期停用钙调神经磷酸酶抑制剂可行且安全。

研究设计与样本

  • ANZHIT-1是在6个澳大利亚异基因造血干细胞移植中心开展的单倍体造血干细胞移植2期研究,纳入78例血液系统恶性肿瘤患者,中位随访732天(范围28-1728)。
  • 预处理方案为减低强度预处理46例和清髓性预处理32例;减低强度预处理包括氟达拉滨、环磷酰胺和200 cGy全身照射,清髓性预处理为静脉氟达拉滨和白消安。
  • 移植物抗宿主病预防采用移植后环磷酰胺、吗替麦考酚酯和钙调神经磷酸酶抑制剂;符合条件患者在移植后第60天开始逐渐减量钙调神经磷酸酶抑制剂,并在第120天前停用。
  • 主要终点为造血干细胞移植后2年无病生存率和总生存率。

主要发现

  • 2年无病生存率在清髓性预处理组为67.5%(95%CI 53.2-85.6),在减低强度预处理组为68.3%(95%CI 56.3-83.01)。
  • 第100天移植相关死亡率在清髓性预处理组为4.9%(95%CI 1.6-15.3),在减低强度预处理组为3.1%(95%CI 0.8-12)。
  • 1年移植相关死亡率在清髓性预处理组为17.9%(95%CI 8.8-36.5),在减低强度预处理组为11.6%(95%CI 6-22.4)。
  • 计划停用钙调神经磷酸酶抑制剂的中位时间为142.5天,未观察到慢性移植物抗宿主病或死亡率增加。
  • 可评估患者中71.6%在移植后12个月停用免疫抑制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haploidentical hematopoietic stem cell transplant (haplo-HSCT) using posttransplant cyclophosphamide (PTCy) is appropriate for those who lack matched donors. Most studies using PTCy have been retrospective making conclusions difficult. ANZHIT-1 was a phase 2 study conducted at 6 Australian allogeneic HSCT centers. The primary end points were disease-free and overall survival at 2 years after HSCT. The reduced-intensity conditioning (RIC) included fludarabine, cyclophosphamide, and 200 cGy total body irradiation, and the myeloablative conditioning (MAC) was IV fludarabine and busulfan. PTCy, MMF and a calcineurin inhibitor (CNI) were used for graft-versus-host disease (GVHD) prophylaxis. CNIs were weaned and ceased by day +120 in eligible patients on day 60. Patients (n = 78) with hematological malignancies were included in the study, with a median follow-up of 732 days (range, 28-1728). HSCT was RIC in 46 patients and MAC in 32 patients. Disease-free survival probability at 2 years was 67.5% (95% [CI], 53.2-85.6) for MAC recipients and 68.3% (95% CI, 56.3-83.01) for RIC recipients. Transplant-related mortality (TRM) on day 100 and year 1 was 4.9% (95% CI, 1.6-15.3) and 17.9% (95% CI, 8.8-36.5), respectively, in the MAC group compared with 3.1% (95% CI, 0.8.1-12) and 11.6% (95% CI, 6-22.4), respectively, in the RIC group. The median time for elective cessation of CNI was day 142.5 days, with no excess chronic GVHD (cGVHD) or mortality. Of the evaluable patients, 71.6% discontinued immunosuppression 12 months after transplant. This prospective haplo-HSCT trial using PTCY demonstrated encouraging survival rates, indicating that early CNI withdrawal is feasible and safe.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Moore J, Hamad N, Gottlieb D, et al. Early cessation of calcineurin inhibitors is feasible post-haploidentical blood stem cell transplant: the ANZHIT 1 study. Blood Adv. 2023. PMID: 37467011. doi:10.1182/bloodadvances.2023009840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。